Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KHK | P50053 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30063067 | 1.00 | ALDH1A1 (0.53) | ALDH1A1NPSR1TDP1KHKCYP11B2 | |
| SCHEMBL30681117 | 0.78 | ALDH1A1 (0.56) | ALDH1A1NPSR1TDP1KHKCYP11B2 | |
| SCHEMBL1031743 | 0.78 | ALDH1A1 (0.56) | ALDH1A1NPSR1TDP1KHKCYP11B2 | |
| SCHEMBL7216099 | 0.77 | ALDH1A1 (0.55) | ALDH1A1NPSR1TDP1KHKCYP11B2 | |
| SCHEMBL30681150 | 0.77 | ALDH1A1 (0.55) | ALDH1A1NPSR1TDP1KHKCYP11B2 | |
| SCHEMBL25302869 | 0.75 | CHRNB2 (0.40) | CYP11B2CYP11B1GRM5 | |
| SCHEMBL1164261 | 0.75 | ALDH1A1 (0.53) | ALDH1A1NPSR1TDP1KHKCYP11B2 | |
| SCHEMBL921763 | 0.75 | KHK (0.43) | ALDH1A1KHKCYP11B2CYP11B1CSNK1A1 | |
| SCHEMBL13082590 | 0.75 | CHRNB2 (0.40) | CYP11B2CYP11B1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2698043 | 0.75 | ALDH1A1 (0.53) | ALDH1A1NPSR1TDP1KHKCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 472 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116239593-B | Preparation method of vitamin Li Xigu intermediate | 上海裕兰生物科技有限公司 | 2025-05-02 | — | — | CN | claimed |
| CN-117700412-A | Impurity of Anrad Wei Gongyi and preparation and detection methods thereof | 广东众生睿创生物科技有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-116239593-A | Preparation method of vitamin Li Xigu intermediate | 上海裕兰生物科技有限公司 | 2023-06-09 | — | — | CN | claimed |
| CN-103012257-A | Quinolone intermediate synthesis technology | Sheng yinuo | 2013-04-03 | — | — | CN | claimed |
| CN-1003236-B | Preparation method of 6, 7-disubstituted-1-cyclopropyl-1, 4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acid | 拜尔公司 | 1989-02-08 | — | — | CN | claimed |
| EP-4746972-A1 | DEUTERATED PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
| US-12508268-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2025-12-30 | — | — | US | disclosed |
| EP-3820860-B1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| US-12312340-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | AVILAR THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2025-05-13 | — | — | US | disclosed |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | ABBVIE INC. | 2006-03-09 | — | — | US | disclosed |
| EP-1626045-A1 | PROCESSES FOR PRODUCING 3-SUBSTITUTED 2-CHLORO-5-FLUOROPYRIDINE OR SALT THEREOF | Asahi Glass Company, Limited (JP) | 2006-02-15 | — | — | EP | disclosed |
| EP-1625123-A2 | 3-(2-AMINO-1-AZACYCLYL)-5-ARYL-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005111003-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
| CN-1613849-A | Preparation of 2-Cl-5-F-nicotinate and nicotonic acid | YAOMING KANGDE MEDICINE DEVELO (CN) | 2005-05-11 | — | — | CN | disclosed |
| CN-1571771-A | Process for preparing beta-ketoester compound | LG LIFE SCIENCES LTD (KR) | 2005-01-26 | — | — | CN | disclosed |
| WO-2004103279-A2 | 3-(2-AMINO-1-AZACYCLYL)-5-ARYL-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| CN-86100126-A | 6, the two replacement-1-cyclopropyl of 7--1,4 dihydro-4-oxo-1, the preparation method and the application thereof of 8-naphthyridines-3-carboxylic acid | — | 1986-07-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312340-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | ASGR1, FCGR2A, FCGR3B | ALDH1A1 3256/4885NPSR1 499/4885TDP1 3940/4885 |
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | ALDH1A1 4287/4885NPSR1 4407/4885TDP1 3874/4885 |
| US-12508268-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | IDO1, IDO2, TDO2 | ALDH1A1 732/4885NPSR1 223/4885TDP1 841/4885 |
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | ALDH1A1 3256/4885NPSR1 499/4885TDP1 3940/4885 |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | ALDH1A1 3578/4885NPSR1 109/4885TDP1 4683/4885 |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | P2RX7, P2RX2, P2RX3 | ALDH1A1 3045/4885NPSR1 198/4885TDP1 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.